New anaesthetic approved

Article

Akten Ophthalmic Gel 3.5%, a topical anaesthetic for the eye, has become the first new ocular anaesthetic to receive FDA approval in 40 years, according to a statement released by Akorn, Inc, the maker of Akten.

Akten Ophthalmic Gel 3.5%, a topical anaesthetic for the eye, has become the first new ocular anaesthetic to receive FDA approval in 40 years, according to a statement released by Akorn, Inc., the maker of Akten.

Akten, a preservative-free lidocaine gel, is suitable for all ocular procedures requiring administration of a topical anaesthetic, either in hospital or in an office. The gel is designed to be stored at room temperature.

The approval follows Akorn's New Drug Application filing in June 2007, which was submitted after the Phase III clinical trial achieved its primary endpoint. Akorn plans to make Akten available before the end of the month.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.